Palatin Technologies (PTN) 0.93 $PTN
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
PR Newswire - Wed Jul 09, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/910,422 (the '422 application). The application includes composition of matter claims on broad families of melanocortin receptor--1 specific peptides with potential utility for treatment of inflammatory diseases and disorders.
Palatin Technologies to Join Russell Microcap Index
PR Newswire - Fri Jun 27, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it is joining the Russell Microcap® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes later today. Palatin was included on a preliminary list of additions posted on www.russell.com/indexes.
Palatin Technologies awarded notice of patent protection for next generation of new peptides that target the melanocortin-4 receptor
M2 - Wed Jun 11, 6:12AM CDT
Biopharmaceutical company Palatin Technologies (NYSE MKT
TN) disclosed on Tuesday that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the composition of matter claims on a next generation of melanocortin receptor-specific peptides for sexual dysfunction, obesity & metabolic syndrome.
Palatin Technologies Announces Notification of Patent Allowance On Next Generation Melanocortin Receptor-Specific Peptides
PR Newswire - Tue Jun 10, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/311,824 (the '824 application). The application includes composition of matter claims on a next generation of melanocortin receptor-specific peptides for sexual dysfunction, obesity, metabolic syndrome and other indications.
Palatin Technologies Inc. (PTN) Jumps: Stock Up 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 7:51AM CDT
Palatin Technologies Inc. was a big mover last session, as its shares rose over 8% on the day.
Palatin Technologies' option to license out Bremelanotide in Europe extended until 30 April 2014
M2 - Tue Apr 01, 6:32AM CDT
Biopharmaceutical company Palatin Technologies (NYSE MKTTN) said on Monday that it has received an extension until 30 April 2014 to an existing option agreement with a potential European partner for an exclusive license to the former's bremelanotide for female sexual dysfunction in selected European countries, including the EU.
Palatin Technologies Announces Option Extension for License to Bremelanotide in Europe
PR Newswire - Mon Mar 31, 3:15PM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has granted an extension until April 30, 2014 to an existing option agreement with a potential commercial partner for an exclusive license to bremelanotide for female sexual dysfunction indications in selected European countries, including the European Union.
Morning Briefing on Stocks hitting New Milestones -- Research on Finisar, Analog Devices, Palatin Technologies and Green Plains Renewable
PR Newswire - Fri Mar 21, 5:04PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite finished at 4,319.29, up 0.27%. The Dow Jones Industrial Average closed the session at 16,331.05, up 0.67% and the S&P 500 ended the day at 1,872.01, higher by 0.60%. The gains were broad based with nine out of 10 sectors ending the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Finisar Corp. (NASDAQ: FNSR), Analog Devices Inc. (NASDAQ: ADI), Palatin Technologies Inc. (AMEX: PTN) and Green Plains Renewable Energy Inc. (NASDAQ: GPRE). Free technical research on FNSR, ADI, PTN and GPRE can be downloaded upon signing up at:
Palatin Technologies (PTN) Worth Watching: Stock Soars 15.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 8:25AM CDT
Palatin was a big mover last session, with shares rising nearly 16% on the day.
Palatin Technologies To Present At The 26Th Annual ROTH Conference
PR Newswire - Thu Mar 06, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 26th Annual ROTH Conference on Tuesday, March 11, 2014, at 3:30 p.m. Pacific Time. The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA.
Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder
PR Newswire - Mon Feb 24, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD), both which are forms of female sexual dysfunction (FSD).1,2,3
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on February 18, 2014
PR Newswire - Tue Feb 18, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2013.
Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PR Newswire - Fri Feb 14, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.
Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2014 Results
PR Newswire - Thu Feb 13, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2014 operating results on Tuesday, February 18, 2014 before the open of the U.S. financial markets.
Palatin Technologies to Present at the 16th Congress of the European Society for Sexual Medicine
PR Newswire - Thu Jan 30, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunctions will be presented at the 16th Congress of the European Society for Sexual Medicine in Istanbul, Turkey on Friday, January 31, 2014 at 3:25 PM local time.
Palatin Technologies awarded USD1.85m in tax credits
M2 - Fri Jan 24, 4:59AM CST
US-based biopharmaceutical company Palatin Technologies Inc (NYSE MKTTN) reported on Thursday the receipt of about USD1.85m of non-dilutive funding via the State of New Jersey's Technology Business Tax Certificate Transfer Programme (the programme).
Palatin Technologies, Inc. Receives $1.85 Million from Sale of New Jersey State Tax Credits
PR Newswire - Thu Jan 23, 8:15AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that it has received approximately $1.85 million of non-dilutive funding via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program).
Palatin Technologies to participate at Noble Financial Capital Markets' Tenth Annual Equity Conference
M2 - Mon Jan 20, 8:11AM CST
Biopharmaceutical company Palatin Technologies Inc (NYSE MKTTN) said on Friday that it will give a presentation at 'TEN', Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida.
Palatin Technologies to Present at "TEN", Noble Financial Capital Markets' Tenth Annual Equity Conference
PR Newswire - Thu Jan 16, 3:00PM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), announced today that Dr. Carl Spana, President and Chief Executive Officer, will present at "TEN", Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Monday, January 20, 2014 at 11:30 a.m. Eastern Time.
Palatin Technologies Responds to Unusual Market Activity
PR Newswire - Mon Jan 13, 3:30PM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) (the "Company"
announced today that in view of the unusual market activity in common stock of the Company on Monday, January 13, 2014, the NYSE MKT (the "Exchange" has contacted the Company in accordance with the Exchange's usual practice. The Company stated that its policy is not to comment on unusual market activity.
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
PR Newswire - Wed Jul 09, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/910,422 (the '422 application). The application includes composition of matter claims on broad families of melanocortin receptor--1 specific peptides with potential utility for treatment of inflammatory diseases and disorders.
Palatin Technologies to Join Russell Microcap Index
PR Newswire - Fri Jun 27, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it is joining the Russell Microcap® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes later today. Palatin was included on a preliminary list of additions posted on www.russell.com/indexes.
Palatin Technologies awarded notice of patent protection for next generation of new peptides that target the melanocortin-4 receptor
M2 - Wed Jun 11, 6:12AM CDT
Biopharmaceutical company Palatin Technologies (NYSE MKT
TN) disclosed on Tuesday that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the composition of matter claims on a next generation of melanocortin receptor-specific peptides for sexual dysfunction, obesity & metabolic syndrome. Palatin Technologies Announces Notification of Patent Allowance On Next Generation Melanocortin Receptor-Specific Peptides
PR Newswire - Tue Jun 10, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/311,824 (the '824 application). The application includes composition of matter claims on a next generation of melanocortin receptor-specific peptides for sexual dysfunction, obesity, metabolic syndrome and other indications.
Palatin Technologies Inc. (PTN) Jumps: Stock Up 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 7:51AM CDT
Palatin Technologies Inc. was a big mover last session, as its shares rose over 8% on the day.
Palatin Technologies' option to license out Bremelanotide in Europe extended until 30 April 2014
M2 - Tue Apr 01, 6:32AM CDT
Biopharmaceutical company Palatin Technologies (NYSE MKT
TN) said on Monday that it has received an extension until 30 April 2014 to an existing option agreement with a potential European partner for an exclusive license to the former's bremelanotide for female sexual dysfunction in selected European countries, including the EU. Palatin Technologies Announces Option Extension for License to Bremelanotide in Europe
PR Newswire - Mon Mar 31, 3:15PM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has granted an extension until April 30, 2014 to an existing option agreement with a potential commercial partner for an exclusive license to bremelanotide for female sexual dysfunction indications in selected European countries, including the European Union.
Morning Briefing on Stocks hitting New Milestones -- Research on Finisar, Analog Devices, Palatin Technologies and Green Plains Renewable
PR Newswire - Fri Mar 21, 5:04PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite finished at 4,319.29, up 0.27%. The Dow Jones Industrial Average closed the session at 16,331.05, up 0.67% and the S&P 500 ended the day at 1,872.01, higher by 0.60%. The gains were broad based with nine out of 10 sectors ending the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Finisar Corp. (NASDAQ: FNSR), Analog Devices Inc. (NASDAQ: ADI), Palatin Technologies Inc. (AMEX: PTN) and Green Plains Renewable Energy Inc. (NASDAQ: GPRE). Free technical research on FNSR, ADI, PTN and GPRE can be downloaded upon signing up at:
Palatin Technologies (PTN) Worth Watching: Stock Soars 15.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 8:25AM CDT
Palatin was a big mover last session, with shares rising nearly 16% on the day.
Palatin Technologies To Present At The 26Th Annual ROTH Conference
PR Newswire - Thu Mar 06, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 26th Annual ROTH Conference on Tuesday, March 11, 2014, at 3:30 p.m. Pacific Time. The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA.
Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder
PR Newswire - Mon Feb 24, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD), both which are forms of female sexual dysfunction (FSD).1,2,3
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on February 18, 2014
PR Newswire - Tue Feb 18, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2013.
Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PR Newswire - Fri Feb 14, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.
Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2014 Results
PR Newswire - Thu Feb 13, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2014 operating results on Tuesday, February 18, 2014 before the open of the U.S. financial markets.
Palatin Technologies to Present at the 16th Congress of the European Society for Sexual Medicine
PR Newswire - Thu Jan 30, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunctions will be presented at the 16th Congress of the European Society for Sexual Medicine in Istanbul, Turkey on Friday, January 31, 2014 at 3:25 PM local time.
Palatin Technologies awarded USD1.85m in tax credits
M2 - Fri Jan 24, 4:59AM CST
US-based biopharmaceutical company Palatin Technologies Inc (NYSE MKT
TN) reported on Thursday the receipt of about USD1.85m of non-dilutive funding via the State of New Jersey's Technology Business Tax Certificate Transfer Programme (the programme). Palatin Technologies, Inc. Receives $1.85 Million from Sale of New Jersey State Tax Credits
PR Newswire - Thu Jan 23, 8:15AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that it has received approximately $1.85 million of non-dilutive funding via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program).
Palatin Technologies to participate at Noble Financial Capital Markets' Tenth Annual Equity Conference
M2 - Mon Jan 20, 8:11AM CST
Biopharmaceutical company Palatin Technologies Inc (NYSE MKT
TN) said on Friday that it will give a presentation at 'TEN', Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida. Palatin Technologies to Present at "TEN", Noble Financial Capital Markets' Tenth Annual Equity Conference
PR Newswire - Thu Jan 16, 3:00PM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), announced today that Dr. Carl Spana, President and Chief Executive Officer, will present at "TEN", Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Monday, January 20, 2014 at 11:30 a.m. Eastern Time.
Palatin Technologies Responds to Unusual Market Activity
PR Newswire - Mon Jan 13, 3:30PM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) (the "Company"
announced today that in view of the unusual market activity in common stock of the Company on Monday, January 13, 2014, the NYSE MKT (the "Exchange" has contacted the Company in accordance with the Exchange's usual practice. The Company stated that its policy is not to comment on unusual market activity. 
